Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342211 · ClinicalTrials.gov registry record · Phase 2
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01342211: Completed Phase 2 study, sponsored by Pfizer.
NCT01342211 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01342211, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
Primary Outcome
Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.
Interventions
- BIOLOGICAL Placebo
- DRUG Statin
- BIOLOGICAL PF-04950615 (RN316)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT01342211 record still lists
NCT01342211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01342211 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01342211 about?
NCT01342211 is a clinical study titled "A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins". This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
What is the current status of trial NCT01342211?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2011-07. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01342211?
The interventions under investigation include: Placebo (BIOLOGICAL), Statin (DRUG), PF-04950615 (RN316) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01342211?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01342211's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia